- Home
- HNVR vs RAPT Comparison
HNVR vs RAPT Comparison
Compare HNVR & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HNVR
- RAPT
- Stock Information
- Founded
- HNVR 2008
- RAPT 2015
- Country
- HNVR United States
- RAPT United States
- Employees
- HNVR N/A
- RAPT N/A
- Industry
- HNVR Commercial Banks
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- HNVR Finance
- RAPT Health Care
- Exchange
- HNVR Nasdaq
- RAPT Nasdaq
- Market Cap
- HNVR 167.7M
- RAPT 194.2M
- IPO Year
- HNVR 2022
- RAPT 2019
- Fundamental
- Price
- HNVR $22.35
- RAPT $18.00
- Analyst Decision
- HNVR Buy
- RAPT Buy
- Analyst Count
- HNVR 2
- RAPT 5
- Target Price
- HNVR $23.75
- RAPT $33.60
- AVG Volume (30 Days)
- HNVR 13.5K
- RAPT 89.6K
- Earning Date
- HNVR 10-22-2025
- RAPT 11-11-2025
- Dividend Yield
- HNVR 1.80%
- RAPT N/A
- EPS Growth
- HNVR N/A
- RAPT N/A
- EPS
- HNVR 1.53
- RAPT N/A
- Revenue
- HNVR $68,211,000.00
- RAPT N/A
- Revenue This Year
- HNVR N/A
- RAPT N/A
- Revenue Next Year
- HNVR $17.15
- RAPT N/A
- P/E Ratio
- HNVR $14.59
- RAPT N/A
- Revenue Growth
- HNVR 14.14
- RAPT N/A
- 52 Week Low
- HNVR $17.33
- RAPT $5.67
- 52 Week High
- HNVR $27.14
- RAPT $26.56
- Technical
- Relative Strength Index (RSI)
- HNVR 51.96
- RAPT 81.43
- Support Level
- HNVR $22.26
- RAPT $11.19
- Resistance Level
- HNVR $22.81
- RAPT $13.66
- Average True Range (ATR)
- HNVR 0.47
- RAPT 1.04
- MACD
- HNVR -0.03
- RAPT 0.58
- Stochastic Oscillator
- HNVR 21.30
- RAPT 96.62
About HNVR Hanover Bancorp Inc.
Hanover Bancorp Inc is a United States-based banking company. It offers a full range of financial services and employs a complete suite of consumer and commercial banking products and services, including multi-family and commercial mortgages, residential loans, business loans, and lines of credit.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.